Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

NCT00390221 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

621

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

BIOLOGICAL: BIIB019 (Daclizumab High Yield Process)
DRUG: Placebo

Sponsor

Biogen

Collaborators

[object Object]